Journal ArticleDOI
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
W. Ian McDonald,A Compston,Gilles Edan,Donald E. Goodkin,Hans-Peter Hartung,Fred D. Lublin,Henry F. McFarland,Donald W. Paty,Chris H. Polman,Stephen C. Reingold,Magnhild Sandberg-Wollheim,William A. Sibley,Alan J. Thompson,Stanley van den Noort,Brian Y. Weinshenker,Jerry S. Wolinsky +15 more
Reads0
Chats0
TLDR
The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.Abstract:
The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in both time and space. Magnetic resonance imaging is integrated with dinical and other paraclinical diagnostic methods. The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including "monosymptomatic" disease suggestive of MS, disease with a typical relapsing-remitting course, and disease with insidious progression, without clear attacks and remissions. Previously used terms such as "clinically definite" and "probable MS" are no longer recommended. The outcome of a diagnostic evaluation is either MS, "possible MS" (for those at risk for MS, but for whom diagnostic evaluation is equivocal), or "not MS."read more
Citations
More filters
Journal ArticleDOI
The window of therapeutic opportunity in multiple sclerosis : Evidence from monoclonal antibody therapy
Alasdair Coles,Amanda L. Cox,E. Le Page,Joanne L. Jones,S. A. Trip,J. Deans,S. R. Seaman,David Miller,Geoff Hale,Herman Waldmann,D. A. S. Compston +10 more
TL;DR: It is speculated that the beneficial effects of early rescue of neurons and axons from a toxic inflammatory environment, and that prevention of demyelination will prevent long–term axonal degeneration, are currently being tested in a controlled trial comparing Campath–1H and IFN–beta in the treatment of drug–naïve patients with early, active RR MS.
Journal ArticleDOI
Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis: A Consensus Statement
Mark S. Freedman,Edward J. Thompson,Florian Deisenhammer,Gavin Giovannoni,Guy Grimsley,Geoffrey Keir,Sten Öhman,Michael K. Racke,Mohammad K. Sharief,Christian Sindic,Finn Sellebjerg,Wallace W. Tourtellotte +11 more
TL;DR: In this article, the authors proposed new criteria for the diagnosis of multiple sclerosis (MS) using both clinical and paraclinical criteria, the latter involving information obtained from magnetic resonance imaging, evoked potentials, and cerebrospinal fluid (CSF) analysis.
Journal ArticleDOI
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Amit Bar-Or,Peter A. Calabresi,Douglas L. Arnold,Clyde E. Markowitz,Stuart Shafer,Lloyd H. Kasper,Emmanuelle Waubant,Suzanne Gazda,Robert J. Fox,Michael Panzara,Neena Sarkar,Sunil Agarwal,Craig H. Smith +12 more
TL;DR: An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy, and events were limited to mild‐to‐moderate infusion‐associated events, which tended to decrease with subsequent infusions.
Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis
Mark S. Freedman,Edward J. Thompson,Florian Deisenhammer,Gavin Giovannoni,Guy Grimsley,Geoffrey Keir,Sten Öhman,Michael K. Racke,Mohammad K. Sharief,Christian Sindic,Finn Sellebjerg,Wallace W. Tourtellotte +11 more
TL;DR: Recommendations for establishing a standard for the evaluation of CSF in patients suspected of having MS should greatly complement the new criteria in ensuring that a correct diagnosis of MS is being made.
Journal ArticleDOI
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol,Frederik Barkhof,P Chang,Patricia K. Coyle,Douglas Jeffery,Steven R. Schwid,B Stubinski,Bernard M. J. Uitdehaag +7 more
TL;DR: There was no significant difference between interferon beta-1a and glatiramer acetate in the primary outcome, and the ability to predict clinical superiority on the basis of results from previous studies might be limited by a trial population with low disease activity.
References
More filters
Journal ArticleDOI
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Charles M. Poser,Donald W. Paty,Labe C. Scheinberg,W I McDonald,F A Davis,George C. Ebers,Kenneth P. Johnson,William A. Sibley,Donald H. Silberberg,Wallace W. Tourtellotte +9 more
TL;DR: Today there is a need for more exact criteria than existed earlier in order to conduct therapeutic trials in multicenter programs, to compare epidemiological surveys, to evaluate new diagnostic procedures, and to estimate the activity of the disease process in MS.
Journal ArticleDOI
The clinical course of neuromyelitis optica (Devic's syndrome)
TL;DR: Clinical, laboratory, and imaging features generally distinguish neuromyelitis optica from MS, and patients with relapsing optic neuritis and myelitis may have neuromyeliitis opticas rather than MS.
Journal ArticleDOI
Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis.
George A. Schumacher,Gilbert Beebe,Robert F. Kibler,Leonard T. Kurland,John F. Kurtzke,Fletcher McDowell,Benedict Nagler,William A. Sibley,Wallace W. Tourtellotte,Thomas L. Willmon +9 more
TL;DR: Since its etiology and pathogenesis have eluded detection, it is not surprising that therapeutic attempts have been empiric and often unscientific.
Journal ArticleDOI
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Frederik Barkhof,Massimo Filippi,David Miller,Philip Scheltens,Adriana Campi,Chris H. Polman,Giancarlo Comi,Herman J. Adèr,N. A. Losseff,Jacob Valk +9 more
TL;DR: It is concluded that a four-parameter dichotomized MRI model including gadolinium-enhancement, juxtacortical, infratentorial and periventricular lesions best predicts conversion to clinically definite multiple sclerosis.
Journal ArticleDOI
MRI in the diagnosis of MS A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT
Donald W. Paty,Joel Oger,Lorne F. Kastrukoff,S. A. Hashimoto,John P. Hooge,Andrew Eisen,K. A. Eisen,S. J. Purves,M. D. Low,V. Brandejs,W. D. Robertson,David Kb Li +11 more
TL;DR: MRI was the best method for demonstrating dissemination in space and laboratory-supported definite MS (LSDMS) could be diagnosed in 85 patients of the total 200, and MRI predicted that diagnosis in 18/19 (95%).
Related Papers (5)
Rating neurologic impairment in multiple sclerosis An expanded disability status scale (EDSS)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more